WO2023281381A1 - SYNERGIC ANTIBACTERIAL COMBINATION OF SCUTELLARIA LATERIFLORA EXTRACT AND CISTUS x INCANUS EXTRACT - Google Patents
SYNERGIC ANTIBACTERIAL COMBINATION OF SCUTELLARIA LATERIFLORA EXTRACT AND CISTUS x INCANUS EXTRACT Download PDFInfo
- Publication number
- WO2023281381A1 WO2023281381A1 PCT/IB2022/056177 IB2022056177W WO2023281381A1 WO 2023281381 A1 WO2023281381 A1 WO 2023281381A1 IB 2022056177 W IB2022056177 W IB 2022056177W WO 2023281381 A1 WO2023281381 A1 WO 2023281381A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- cistus
- incanus
- synergic
- scutellaria lateriflora
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 235000000350 Cistus incanus Nutrition 0.000 title claims abstract description 16
- 241000866387 Cistus incanus Species 0.000 title claims abstract description 16
- 241000632296 Scutellaria lateriflora Species 0.000 title claims abstract description 16
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 14
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 8
- 210000000214 mouth Anatomy 0.000 claims abstract description 12
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 6
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 6
- 229960003321 baicalin Drugs 0.000 claims abstract description 6
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 6
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002324 mouth wash Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 235000002548 Cistus Nutrition 0.000 description 7
- 241000984090 Cistus Species 0.000 description 7
- 241000207929 Scutellaria Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 241000605862 Porphyromonas gingivalis Species 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000001974 tryptic soy broth Substances 0.000 description 6
- 108010050327 trypticase-soy broth Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 201000001245 periodontitis Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 2
- 229940015301 baicalein Drugs 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000519996 Teucrium chamaedrys Species 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the object of the present invention is a synergic combination of Scutellaria lateriflora L. extract titrated in baicalin and Cistus x incanus L. extract with a high polyphenol content, for the health of the oral cavity.
- the human body coexists with various micro-organisms which live in all its organs and on all its surfaces in constant symbiosis. Since 2007 the scientific community has investigated the relationships between bacterial flora, human physiology and the onset and chronicisation of diseases, demonstrating that bacteria actively influence human physiology at a systemic level, and modulate the overall health of human beings.
- the bacterial flora of the oral cavity is an essential part of the human microbiome, and is represented by over six billion bacteria belonging to 700 different species. It is highly dynamic due to numerous factors, such as genetics, oral hygiene and lifestyle, including smoking and diet. Diet plays a key role because micro-organisms feed on food debris remaining in the oral cavity after meals; depending on the predominant macronutrients (carbohydrates or proteins), different species of micro-organisms can colonize the oral cavity more easily because they use preferential metabolic and fermentation pathways; fluctuations in pH affect the growth of specific bacterial species to the disadvantage of others, inducing eubiosis/dysbiosis.
- Periodontal disease infections of the supporting structures around the tooth, such as gums and bone
- cardio- and cerebrovascular diseases asthma, pneumonia, premature births and pre-eclampsia, epilepsy, and osteoporosis.
- the connection between periodontal disease and secondary systemic disorders may be due to the diffusion of the infection from the oral cavity to other organs via the blood circulation of microbial toxins, and a systemic inflammatory state generated by buccal inflammation.
- periodontitis is a multifactorial polymicrobial infection characterized by a destructive inflammatory process.
- Porphyromonas gingivalis a Gram-negative black- pigmented anaerobe bacterium, is a major pathogen involved in the initiation and progression of periodontitis; it is able to produce a plethora of virulence factors that stimulate human gingival epithelium (HIGh) cells and human periodontal ligament (HPL) cells to produce various inflammatory mediators.
- HOGh human gingival epithelium
- HPL human periodontal ligament
- Chlorhexidine is used in mouthwashes and, though effective in reducing inflammation of bacterial origin, may induce resistance and also has an indiscriminate bactericidal action, acting not only against pathogens, but also against eubiotic bacteria, causing dysbiosis.
- Medicinal plants are traditionally used as antibacterials because they contain bioactive substances such as polyphenols and essential oils.
- bilberry helps control and reduce the risk of oral cavity inflammations (Widen et ah, Acta Odontol Scand. 2015;73(7):539-43); magnolia, cinnamon and aloe vera extracts help prevent plaque and the onset of gingivitis (clinically tested, Hellstrom et ah, Int J Dent Hyg. 2014 May; 12(2): 96- 102; Gupta et ah, J Int Acad Periodontol. 2015 Jul;17(3):91-8; Yeturu et ah, J Oral Biol Craniofac Res.
- Scutellaria lateriflora L. is a typical nerve-soothing plant, which is widely used, especially in North America, as a hypnotic and sedative; the rationale for said use is that the flavonoids characteristic of said plant, baicalein and wogonin, exert tranquilizing effects by means of allosteric modulation of the GABA (g-aminobutyric acid) receptor on the benzodiazepine site (Hui et al., Biochem Pharmacol.
- Infusions obtained from various species of Cistus have traditionally been used to soothe disorders of the digestive and respiratory tracts, and for some skin problems.
- the antioxidant properties of said plant are also known (Gori et al., Int J Mol Sci. 2016 Aug 17; 17(8): 1344).
- the efficacy of the plant against Gram-positive bacteria has also been known for some time (Kuchta et al., Cardiol J. 2019 Mar 26).
- Another in vitro study demonstrated the antibacterial and antiadhesion activity of a Cistus x incanus L. extract against Streptococcus mutans (Wittpahl et al., Planta Med. 2015 Dec;81(18): 1727-35).
- Said combination can be advantageously used as an ingredient of foods in current or functional use (candies, chewing gums, fruit juices and beverages) and for food supplements and medical devices which, in view of their everyday consumption/use, direct the composition of the oral microbiota towards eubiosis, reducing pathogenic bacteria and thus performing a protective action against diseases of the oral cavity and the systemic diseases connected with them.
- the first aspect of the invention relates to a synergic antibacterial combination consisting of a Scutellaria lateriflora L. extract and a Cistus x incanus L. extract.
- the tested combination in the form of a solution or suspension, is characterized by weight/volume concentration ratios of the Scutellaria lateriflora L. extract and the Cistus x incanus L. extract ranging between 3 : 1 and 1:1, respectively.
- the Scutellaria lateriflora L. and Cistus x incanus L. extracts are preferably water-alcohol extracts.
- Said extracts are known or obtainable by known methods. See, for example DE 202005 014459, US 8,691,294, EP 1 446 135 and US 7,771,758.
- the Scutellaria lateriflora L. extract preferably has a baicalin content of not less than 10% by weight, while the Cistus x incanus L. extract preferably has a polyphenol content ranging between 18 and 25% by weight.
- the Scutellaria lateriflora L. extract with minimum baicalin content of 10%, used in the synergic combination, can be prepared, after identification by DNA barcoding test (to rule out contamination with other morphologically similar species of the same genus, and above all with the dangerous Teucrium chamaedrys ), by a process including the following steps: the pre-dried aerial parts are chopped, preferably to a length of 1-2 cm; they are treated with an extractive solvent containing water, ethanol and/or mixtures thereof; the mixture is maintained in percolation under heating; at the end of the first recycle, the extraction is repeated under the same conditions 3 to 5 times, using fresh solvent every time. All the water-alcohol extracts are combined, filtered, and concentrated; the extractive solvents are removed by concentration under vacuum, under heating, and subsequent spray-drying on maltodextrin, until a homogeneous greenish- brown powder is obtained.
- the Cistus x incanus L. extract with a polyphenol content ranging between 18 and 25% can be prepared by a method including the following steps: the pre-dried aerial parts are chopped, preferably to a length of 1-2 cm; then they are treated with an extractive solvent containing water, ethanol and/or mixtures thereof; the mixture is maintained in percolation under heating; at the end of the first recycle, the extraction is repeated under the same conditions 3 to 5 times, using fresh solvent every time. All the water-alcohol extracts are combined, filtered, and concentrated; the extractive solvents are removed by concentration under vacuum, under heating, and subsequent spray-drying on gum arabic until a homogeneous brown powder is obtained.
- the synergic combination according to the invention is appropriately formulated in compositions suitable for use in applications in the oral hygiene field, for example in the form of mouthwashes, gels, pastes, chewing gums, chewable tablets, or orodispersible films.
- concentrations of the extracts in the compositions can range within wide limits; broadly speaking they will range between 1 and 100 mg/ml per extract.
- Porphyromonas gingivalis was cultured in Trypticase Soy Broth (TSB) in anaerobic conditions, and seeded in a 96-well multiwell plate at an optical density of 0.1 OD, then treated with the extracts for 24 hours.
- TLB Trypticase Soy Broth
- Porphyromonas gingivalis the strain was obtained from the American Type Culture Collection (ATCC 33277) and cultured according to the supplier’s instructions in TSB culture broth.
- Atmosphere anaerobic
- the anaerobic conditions were obtained by using an anaerobic jar and AnaeroGen® Compact paper sachets (Thermo Scientific - AN0025A).
- the freeze-dried strain was rehydrated with 1 ml of TSB under sterile conditions. About 100 m ⁇ of the bacterial suspension was used to inoculate a plate of TSA agar. The bacterial suspension and the plate were incubated at 37°C, under anaerobic conditions for 24-48 hours, until the turbidity increased and colonies appeared.
- the micro-organism was seeded in TSB in a 96-well plate at an optical density of 0.1 OD, and then treated with the extracts for 24 hours.
- concentrations tested were 60, 50, 40, 30, 20, 10 and 5 mg/mL, and each test was conducted in triplicate.
- the extracts were diluted in sterile culture broth. 10 pg/ml of the antibiotic amoxicillin was used as positive control. Incubation was conducted anaerobically at 37°C for 24 hours.
- the absorbance was read at the wavelength of 595 nm.
- the absorbance value is directly proportional to bacterial growth.
- the absorbance data are shown in the graph.
- the significant differences between the groups were evaluated by ANOVA test, using GraphPad Prism 6.0.
- the data are expressed as mean ⁇ standard deviation (SD) of three independent experiments.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a synergic combination of Scutellaria lateriflora L. extract titrated in baicalin and Cistus x incanus L. extract with a high polyphenol content, for the health of the oral cavity.
Description
SYNERGIC ANTIBACTERIAL COMBINATION OF SCUTELLARIA
LATERIFLORA EXTRACT AND CISTUS x INCANUS EXTRACT
SUMMARY OF THE INVENTION
The object of the present invention is a synergic combination of Scutellaria lateriflora L. extract titrated in baicalin and Cistus x incanus L. extract with a high polyphenol content, for the health of the oral cavity. PRIOR ART
The human body coexists with various micro-organisms which live in all its organs and on all its surfaces in constant symbiosis. Since 2007 the scientific community has investigated the relationships between bacterial flora, human physiology and the onset and chronicisation of diseases, demonstrating that bacteria actively influence human physiology at a systemic level, and modulate the overall health of human beings.
The bacterial flora of the oral cavity is an essential part of the human microbiome, and is represented by over six billion bacteria belonging to 700 different species. It is highly dynamic due to numerous factors, such as genetics, oral hygiene and lifestyle, including smoking and diet. Diet plays a key role because micro-organisms feed on food debris remaining in the oral cavity after meals; depending on the predominant macronutrients (carbohydrates or proteins), different species of micro-organisms can colonize the oral cavity more easily because they use preferential metabolic and fermentation pathways; fluctuations in pH affect the growth of specific bacterial species to the disadvantage of others, inducing eubiosis/dysbiosis. It is therefore clear that diet, partly as it affects the health of the oral cavity, plays an important role in health at a systemic level, as demonstrated for the first time in 1980. Periodontal disease (infections of the supporting structures around the tooth, such as gums and bone) is known to be associated with cardio- and cerebrovascular diseases, asthma, pneumonia, premature births and pre-eclampsia, epilepsy, and osteoporosis. The connection between periodontal disease and secondary systemic disorders may be due to
the diffusion of the infection from the oral cavity to other organs via the blood circulation of microbial toxins, and a systemic inflammatory state generated by buccal inflammation.
In detail, periodontitis is a multifactorial polymicrobial infection characterized by a destructive inflammatory process. Porphyromonas gingivalis, a Gram-negative black- pigmented anaerobe bacterium, is a major pathogen involved in the initiation and progression of periodontitis; it is able to produce a plethora of virulence factors that stimulate human gingival epithelium (HIGh) cells and human periodontal ligament (HPL) cells to produce various inflammatory mediators.
To reduce oral cavity infections, widespread use has been made of chi orhexi dine, a broad-spectrum disinfectant active against Gram-positive bacteria, some species of Pseudomonas and Proteus , and some fungi and viruses. Chlorhexidine is used in mouthwashes and, though effective in reducing inflammation of bacterial origin, may induce resistance and also has an indiscriminate bactericidal action, acting not only against pathogens, but also against eubiotic bacteria, causing dysbiosis.
To reduce the side effects of chlorhexidine, the use of mouthwashes based on plant extracts has been proposed in recent years as a good alternative to the use of said antiseptic.
Medicinal plants are traditionally used as antibacterials because they contain bioactive substances such as polyphenols and essential oils.
Data relating to the use of plants and extracts to obtain a positive, synergic action against oral cavity flora are present in the literature: bilberry helps control and reduce the risk of oral cavity inflammations (Widen et ah, Acta Odontol Scand. 2015;73(7):539-43); magnolia, cinnamon and aloe vera extracts help prevent plaque and the onset of gingivitis (clinically tested, Hellstrom et ah, Int J Dent Hyg. 2014 May; 12(2): 96- 102; Gupta et ah, J Int Acad Periodontol. 2015 Jul;17(3):91-8; Yeturu et ah, J Oral Biol Craniofac Res. 2016 Jan-Apr;6(l):54-8); and a product containing multiple extracts (ginger, rosemary and calendula) has proved effective against gingivitis (Mahyari et ah, Complement Ther Clin Pract. 2016 Feb;22:93-8).
Scutellaria lateriflora L. is a typical nerve-soothing plant, which is widely used, especially in North America, as a hypnotic and sedative; the rationale for said use is that the flavonoids characteristic of said plant, baicalein and wogonin, exert tranquilizing effects by means of allosteric modulation of the GABA (g-aminobutyric acid) receptor on the benzodiazepine site (Hui et al., Biochem Pharmacol. 2002 Nov 1;64(9): 1415-24; Wang et al., Neuropharmacology. 2008 Dec;55(7):1231-7). Moreover, many ingredients and extracts of the genus Scutellaria have exhibited antibacterial activity in vitro (Shen et al., J Ethnopharmacol. 2021 Jan 30;265: 113198), but only limited tests have been conducted on Scutellaria lateriflora L. extracts, and only with some pathogens (Bergeron et al., International Journal of Pharmacognosy, 34:4, 233-242). More recently, baicalin has exhibited synergism against S. aureus when combined with the beta-lactam antibiotic benzylpenicillin (Liu et al., J Pharm Pharmacol. 2000 Mar;52(3):361-6). In a very recent study, its aglycone baicalein exhibited significant inhibitory properties against biofilm formation by Streptococcus mutans (Vijayakumar et al., Antibiotics 2021, 10, 215), one of the main cariogenic species, which is considered to be the pioneer bacterium in the colonization of the tooth surface.
Infusions obtained from various species of Cistus have traditionally been used to soothe disorders of the digestive and respiratory tracts, and for some skin problems. The antioxidant properties of said plant are also known (Gori et al., Int J Mol Sci. 2016 Aug 17; 17(8): 1344). The efficacy of the plant against Gram-positive bacteria has also been known for some time (Kuchta et al., Cardiol J. 2019 Mar 26). Another in vitro study demonstrated the antibacterial and antiadhesion activity of a Cistus x incanus L. extract against Streptococcus mutans (Wittpahl et al., Planta Med. 2015 Dec;81(18): 1727-35).
DESCRIPTION OF THE INVENTION
It has now been found that a combination of Scutellaria lateriflora L. and Cistus x incanus L. extracts exhibits synergic antimicrobial activity against Porphyromonas gingi al is, a bacterium that causes periodontitis.
Said combination can be advantageously used as an ingredient of foods in current
or functional use (candies, chewing gums, fruit juices and beverages) and for food supplements and medical devices which, in view of their everyday consumption/use, direct the composition of the oral microbiota towards eubiosis, reducing pathogenic bacteria and thus performing a protective action against diseases of the oral cavity and the systemic diseases connected with them.
Therefore, the first aspect of the invention relates to a synergic antibacterial combination consisting of a Scutellaria lateriflora L. extract and a Cistus x incanus L. extract.
The tested combination, in the form of a solution or suspension, is characterized by weight/volume concentration ratios of the Scutellaria lateriflora L. extract and the Cistus x incanus L. extract ranging between 3 : 1 and 1:1, respectively.
The Scutellaria lateriflora L. and Cistus x incanus L. extracts are preferably water-alcohol extracts.
Said extracts are known or obtainable by known methods. See, for example DE 202005 014459, US 8,691,294, EP 1 446 135 and US 7,771,758.
The Scutellaria lateriflora L. extract preferably has a baicalin content of not less than 10% by weight, while the Cistus x incanus L. extract preferably has a polyphenol content ranging between 18 and 25% by weight.
The Scutellaria lateriflora L. extract with minimum baicalin content of 10%, used in the synergic combination, can be prepared, after identification by DNA barcoding test (to rule out contamination with other morphologically similar species of the same genus, and above all with the dangerous Teucrium chamaedrys ), by a process including the following steps: the pre-dried aerial parts are chopped, preferably to a length of 1-2 cm; they are treated with an extractive solvent containing water, ethanol and/or mixtures thereof; the mixture is maintained in percolation under heating; at the end of the first recycle, the extraction is repeated under the same conditions 3 to 5 times, using fresh solvent every time. All the water-alcohol extracts are combined, filtered, and concentrated; the extractive solvents are removed by concentration under vacuum, under
heating, and subsequent spray-drying on maltodextrin, until a homogeneous greenish- brown powder is obtained.
The Cistus x incanus L. extract with a polyphenol content ranging between 18 and 25% can be prepared by a method including the following steps: the pre-dried aerial parts are chopped, preferably to a length of 1-2 cm; then they are treated with an extractive solvent containing water, ethanol and/or mixtures thereof; the mixture is maintained in percolation under heating; at the end of the first recycle, the extraction is repeated under the same conditions 3 to 5 times, using fresh solvent every time. All the water-alcohol extracts are combined, filtered, and concentrated; the extractive solvents are removed by concentration under vacuum, under heating, and subsequent spray-drying on gum arabic until a homogeneous brown powder is obtained.
The synergic combination according to the invention is appropriately formulated in compositions suitable for use in applications in the oral hygiene field, for example in the form of mouthwashes, gels, pastes, chewing gums, chewable tablets, or orodispersible films. The concentrations of the extracts in the compositions can range within wide limits; broadly speaking they will range between 1 and 100 mg/ml per extract.
The invention is described in detail in the following example.
EXAMPLE
Evaluation of antimicrobial activity against Porphyromonas gingivalis
Porphyromonas gingivalis was cultured in Trypticase Soy Broth (TSB) in anaerobic conditions, and seeded in a 96-well multiwell plate at an optical density of 0.1 OD, then treated with the extracts for 24 hours.
Materials and reagents:
Porphyromonas gingivalis : the strain was obtained from the American Type Culture Collection (ATCC 33277) and cultured according to the supplier’s instructions in TSB culture broth.
Supplemented Tryptic Soy Broth/ Agar (ATCC® Medium 2722)
DI Water -1000 ml
Autocl ave at 121 °C .
Final pH 7.4 +/- 0.2
Stored at 2-8°C.
Growth conditions of micro-organism:
Temperature: 37°C
Atmosphere: anaerobic
The anaerobic conditions were obtained by using an anaerobic jar and AnaeroGen® Compact paper sachets (Thermo Scientific - AN0025A).
The freeze-dried strain was rehydrated with 1 ml of TSB under sterile conditions. About 100 mΐ of the bacterial suspension was used to inoculate a plate of TSA agar. The bacterial suspension and the plate were incubated at 37°C, under anaerobic conditions for 24-48 hours, until the turbidity increased and colonies appeared.
To evaluate the antimicrobial activity of the extracts against Porphyromonas gingivalis , the micro-organism was seeded in TSB in a 96-well plate at an optical density of 0.1 OD, and then treated with the extracts for 24 hours. The concentrations tested were 60, 50, 40, 30, 20, 10 and 5 mg/mL, and each test was conducted in triplicate. The extracts were diluted in sterile culture broth. 10 pg/ml of the antibiotic amoxicillin was used as positive control. Incubation was conducted anaerobically at 37°C for 24 hours.
The absorbance was read at the wavelength of 595 nm. The absorbance value is directly proportional to bacterial growth. The absorbance data are shown in the graph. The significant differences between the groups were evaluated by ANOVA test, using GraphPad Prism 6.0. The data are expressed as mean ± standard deviation (SD) of three independent experiments.
Water-alcohol extracts of Scutellaria lateriflora L. and Cistus x incanus L. were tested on P. gingivalis , first individually and then in the proportion of 1:1, obtaining the following results:
• 30 mg/ml of Scutellaria leads to 16% growth inhibition
• 30 mg/ml of Cistus leads to 4% growth inhibition
• 30 mg/ml of Scutellaria + 30 mg/ml of Cistus (ratio 1 : 1) leads to 48% growth inhibition, i.e.. twice (nearly 2.5 times) as much as what the sum should have been (about 20%).
In light of observed synergism, the following combinations of both extracts were tested, using ampicillin as positive control and broth medium without the addition of the extracts as negative control:
Scutellaria + Cistus 55 mg/mL+5 mg/mL 45 mg/mL+15 mg/mL 40 mg/mL+20 mg/mL 30 mg/mL+30 mg/mL 20 mg/mL+40 mg/mL 10 mg/mL+50 mg/mL 5 mg/mL+55 mg/mL Ampicillin 20 pM/mL
The results obtained, as reported in the annexed Figure, confirmed Scutellaria- Cistus combination synergic activity (ratio 1:1), and indicate that only the mixtures:
45 mg/mL+15 mg/mL 40 mg/mL+20 mg/mL 30 mg/mL+30 mg/mL exhibit a synergic activity towards the individual extracts, indicating that, when a larger amount Scutellaria extract is present with respect to Cistus extract (up to a ratio of 3 : 1), a synergic effect takes place. Conversely, when the Cistus extract is quantitatively more abundant than Scutellaria extract, no synergic effect takes place.
Claims
1. Synergic antibacterial combination consisting of an extract of Scutellaria lateriflora L. and an extract of Cistus x incanus L.
2. Combination according to claim 1 in the form of a solution or suspension.
3. Combination according to claim 2 wherein the weight/volume concentration ratios of the extract of Scutellaria lateriflora L. and the extract of Cistus x incanus L. range between 3:1 and 1:1 respectively.
4. A combination according to any one of claims 1 to 3 wherein the extracts of Scutellaria lateriflora L. and Cistus x incanus L. are water-alcohol extracts.
5. Combination according to claim 4 wherein the extract of Scutellaria lateriflora L. has a baicalin content of not less than 10% by weight.
6. Combination according to claim 4 wherein the extract of Cistus x incanus L. has a polyphenol content ranging between 18 and 25% by weight.
7. Compositions for the hygiene of the oral cavity comprising the combination of claims 1-6.
8. Compositions according to claim 7 in the form of mouthwashes, gels, pastes, chewing gums, chewable tablets and orodispersible films.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247001589A KR20240034757A (en) | 2021-07-08 | 2022-07-04 | Synergistic antibacterial combination of goldenrod extract and Cistus x incanus extract |
| EP22744826.3A EP4366752A1 (en) | 2021-07-08 | 2022-07-04 | Synergic antibacterial combination of scutellaria lateriflora extract and cistus x incanus extract |
| JP2024500150A JP2024525072A (en) | 2021-07-08 | 2022-07-04 | Synergistic antibacterial combination of Scutellaria lateriflora extract and Cistus x Incanus extract |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000018035 | 2021-07-08 | ||
| IT102021000018035A IT202100018035A1 (en) | 2021-07-08 | 2021-07-08 | SYNERGIC ANTIBACTERIAL ASSOCIATION OF SCUTELLARIA LATERIFLORA AND CISTUS x INCANUS EXTRACTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023281381A1 true WO2023281381A1 (en) | 2023-01-12 |
Family
ID=78049599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2022/056177 WO2023281381A1 (en) | 2021-07-08 | 2022-07-04 | SYNERGIC ANTIBACTERIAL COMBINATION OF SCUTELLARIA LATERIFLORA EXTRACT AND CISTUS x INCANUS EXTRACT |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4366752A1 (en) |
| JP (1) | JP2024525072A (en) |
| KR (1) | KR20240034757A (en) |
| IT (1) | IT202100018035A1 (en) |
| WO (1) | WO2023281381A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009011152A1 (en) * | 2009-03-05 | 2010-09-09 | Bionorica Ag | New plant extract hydrolysates of e.g. Equiseti herba and/or Juglandis folium, obtained by hydrolytic treatment with mineral acid, useful e.g. as antibacterial agent for prophylaxis and treatment of infections e.g. rhinitis and sinusitis |
| CN101856452A (en) * | 2010-06-23 | 2010-10-13 | 武伟 | Medicament for treating bronchitis and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6740343B2 (en) | 2001-09-17 | 2004-05-25 | Phytos, Inc. | Standardized extracts of Scutellaria lateriflora |
| US20040109906A1 (en) | 2002-09-06 | 2004-06-10 | Stefan Gafner | Extract of mad-dog skullcap |
| DE202005014459U1 (en) | 2005-09-13 | 2006-01-19 | Pandalis, Georgios, Dr. | Aerosol, useful for treating and/or preventing infections caused by influenza, comprises a plant extract of the genus Cistus |
| DE102007006122A1 (en) | 2007-02-02 | 2008-08-07 | Krewel Meuselbach Gmbh | Cistusextrakte |
-
2021
- 2021-07-08 IT IT102021000018035A patent/IT202100018035A1/en unknown
-
2022
- 2022-07-04 WO PCT/IB2022/056177 patent/WO2023281381A1/en active Application Filing
- 2022-07-04 KR KR1020247001589A patent/KR20240034757A/en unknown
- 2022-07-04 EP EP22744826.3A patent/EP4366752A1/en active Pending
- 2022-07-04 JP JP2024500150A patent/JP2024525072A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009011152A1 (en) * | 2009-03-05 | 2010-09-09 | Bionorica Ag | New plant extract hydrolysates of e.g. Equiseti herba and/or Juglandis folium, obtained by hydrolytic treatment with mineral acid, useful e.g. as antibacterial agent for prophylaxis and treatment of infections e.g. rhinitis and sinusitis |
| CN101856452A (en) * | 2010-06-23 | 2010-10-13 | 武伟 | Medicament for treating bronchitis and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| CHINOU ET AL: "Cytotoxic and antibacterial labdane-type diterpenes from the aerial parts of Cistus incanus subsp. creticus", PLANTA MEDICA, THIEME VERLAG, DE, vol. 60, no. 1, 1 January 1994 (1994-01-01), pages 34 - 36, XP002118275, ISSN: 0032-0943 * |
| DATABASE WPI Week 201109, Derwent World Patents Index; AN 2010-P14490, XP002805706 * |
| SHANG X ET AL: "The genus Scutellaria an ethnopharmacological and phytochemical review", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER IRELAND LTD, IE, vol. 128, no. 2, 24 March 2010 (2010-03-24), pages 279 - 313, XP026939822, ISSN: 0378-8741, [retrieved on 20100306], DOI: 10.1016/J.JEP.2010.01.006 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4366752A1 (en) | 2024-05-15 |
| KR20240034757A (en) | 2024-03-14 |
| JP2024525072A (en) | 2024-07-09 |
| IT202100018035A1 (en) | 2023-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cardoso et al. | Influence of a Brazilian wild green propolis on the enamel mineral loss and Streptococcus mutans’ count in dental biofilm | |
| Aksoy et al. | In vitro and in vivo antimicrobial effects of mastic chewing gum against Streptococcus mutans and mutans streptococci | |
| Shu et al. | Antibacterial activity of quercetin on oral infectious pathogens | |
| Furiga et al. | In vitro study of antioxidant capacity and antibacterial activity on oral anaerobes of a grape seed extract | |
| González et al. | Antibacterial effects of blackberry extract target periodontopathogens | |
| Maripandi et al. | Prevalence of dental caries bacterial pathogens and evaluation of inhibitory concentration effect on different tooth pastes against Streptococcus spp | |
| Smida et al. | Benefits of sea buckthorn (Hippophae rhamnoides) pulp oil‐based mouthwash on oral health | |
| Bomdyal et al. | Antibacterial activity of curcumin (turmeric) against periopathogens-An in vitro evaluation | |
| Kiari et al. | In vitro study on the activity of essential oil and methanolic extract from Algerian Nigella sativa L. Seeds on the growth kinetics of micro-organisms isolated from the buccal cavities of periodontal patients | |
| Esawy et al. | Evaluated bioactive component extracted from Punica granatum peel and its Ag NPs forms as mouthwash against dental plaque | |
| Widyarman et al. | Antibiofilm effect of Clitoria ternatea flower juice on Porphyromonas gingivalis in vitro | |
| Afolabi et al. | Susceptibility of cariogenic Streptococcus mutans to extracts of Garcinia kola, Hibiscus sabdariffa, and Solanum americanum. | |
| Carvalho et al. | The in vitro antimicrobial activity of natural infant fluoride-free toothpastes on oral micro-organisms | |
| Bakhshi et al. | In vitro antibacterial effect of Pimpinella anisum essential oil on Enterococcus faecalis, Lactobacillus casei, Actinomyces naeslundii, and Aggregatibacter actinomycetemcomitans | |
| SHANKAR et al. | Efficacy of Calendula officinalis Extract (Marigold Flower) as an Antimicrobial Agent against Oral Microbes: An Invitro Study in Comparison with Chlorhexidine Digluconate. | |
| KR102232341B1 (en) | Cosmetic composition for preventing or improving skin aging or skin inflammation comprising fermented product of Mentha piperascens leaf and ginger as an active ingredient | |
| KR102207872B1 (en) | Oral composition for preventation or treatment of oral disease | |
| Nurrahman et al. | Effectiveness of Matricaria chamomilla essential oil on Aggregatibacter actinomycetemcomitans and Treponema denticola biofilms | |
| WO2023281381A1 (en) | SYNERGIC ANTIBACTERIAL COMBINATION OF SCUTELLARIA LATERIFLORA EXTRACT AND CISTUS x INCANUS EXTRACT | |
| Demirez Bircan et al. | Comparative evaluation of various herbal extracts on biofilms of Streptococcus mutans and Scardovia wiggsiae: An in vitro study | |
| Elgamily et al. | Laboratory evaluation of anti-plaque and remineralization efficacy of sugarless probiotic jelly candy supplemented with natural nano prebiotic additive | |
| Ansiliero et al. | (Antimicrobial and antioxidant activity of hydroalcoholic extracts of bee propolis (Tetragonisca angustula) and/or Calendula officinalis and potential use in mouthwash formulation/Atividade antimicrobiana e antioxidante de extratos hidroalcoólicos de propolis de abelha (Tetragonisca angustula) e/ou Calendula officinalis e potencial uso na formulação de enxaguantes bucais | |
| Nandan et al. | Effect of green tea as a mouth rinse on Streptococcus mutans | |
| Al-Ezzi et al. | Black and green tea antimicrobial effect on Mutans streptococci and Lactobacilli. | |
| Hirao et al. | Antibacterial effects of cocoa on periodontal pathogenic bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22744826 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2024500150 Country of ref document: JP Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 20247001589 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2022744826 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |